IDEAYA Biosciences, Inc. (IDYA) financials: revenue, earnings and cash flow
Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$114M, a net margin of -52.0%; the best year in this period was 2017 with -$12M.
Over the twelve months to September 30, 2026, revenue was $37M and net income -$420M.
Free cash flow was -$73M in fiscal 2025 and positive in 1 of the 9 years shown.
The diluted share count rose 12625% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37M | $219M | $7M | $23M | $51M | $28M | $20M | $0 | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$463M | -$159M | -$327M | -$134M | -$63M | -$50M | -$35M | -$44M | -$36M | -$14M |
| Net income | -$420M | -$114M | -$274M | -$113M | -$59M | -$50M | -$34M | -$42M | -$34M | -$12M |
| EPS (diluted) | $-4.49 | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.40 | $-3.36 | $-35.92 | $-17.06 |
| R&D | $387M | $315M | $295M | $130M | $90M | $58M | $40M | $34M | $32M | $12M |
| Revenue growth | — | +3024.4% | −70.1% | −54.1% | +82.3% | +43.0% | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$347M | -$71M | -$248M | -$115M | -$87M | -$56M | $55M | -$39M | -$28M | -$12M |
| Capital spending | -$2M | -$2M | -$4M | -$2M | -$3M | -$3M | -$493000 | -$1M | -$2M | -$2M |
| Free cash flow | -$350M | -$73M | -$251M | -$118M | -$91M | -$58M | $55M | -$41M | -$29M | -$14M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Buybacks | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $61M | $46M | $35M | $18M | $12M | $8M | $4M | $2M | $950000 | $136000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $639M | $676M | $525M | $365M | $247M | $284M | $99M | $90M | $6M |
| Debt | — | $28M | $19M | $3M | $3M | $5M | $7M | $7M | $8M | — |
| Equity | — | $1.0B | $1.1B | $621M | $349M | $302M | $198M | $100M | -$49M | -$16M |
| Total assets | — | $1.1B | $1.1B | $649M | $388M | $381M | $298M | $113M | $97M | — |
| Shares (diluted) | 103M | 88M | 82M | 58M | 41M | 35M | 25M | 12M | 1M | 1M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | -1267.4% | -72.8% | -4671.1% | -574.9% | -122.7% | -179.9% | -180.9% | — | — | — |
| Net margin | -1149.6% | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% | -176.6% | — | — | — |
| FCF margin | -957.4% | -33.6% | -3592.0% | -502.9% | -177.9% | -209.1% | 281.3% | — | — | — |
| ROIC | — | -12.0% | -23.9% | -17.0% | -14.0% | -13.0% | -13.6% | -32.6% | — | — |
| ROE | — | -11.1% | -25.9% | -18.2% | -16.8% | -16.5% | -17.4% | -41.8% | 70.2% | 75.4% |
Frequently asked questions
What is IDEAYA Biosciences’s annual revenue?
$219M in fiscal 2025 and $37M over the twelve months to September 30, 2026.
How much profit does IDEAYA Biosciences make?
Net income was -$114M in fiscal 2025 (net margin -52.0%).
Is IDEAYA Biosciences’s revenue growing?
Yes: revenue rose 3024.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.